Evgen’s SFX-01 candidate as a new therapeutic for patients after SAH

Evgen Pharma’s lead product, SFX-01, has been featured in a recently published paper, in the journal “Oxidative Medicine and Cellular Longevity”, describing Phase IIb trial in subarachnoid haemorrhage (“SAH”) at University Hospital Southampton.

The review details the different mechanisms of injury after SAH, summarises evidence that the Nrf2 pathway is active and protective after SAH and comments on the substantial preclinical evidence for the therapeutic potential of SFN as an Nrf2 activator.

The paper states that: “In many respects, SFN would appear to be an excellent candidate as a new therapeutic for patients after SAH. The lack of a practical formulation for clinical use has prevented trials to date. However, SFX-01 (Evgen Pharma) represents a novel solution to this by complexing SFN with α-cyclodextrin to produce a stable powder that can be used clinically.”

The paper can be viewed at:  https://doi.org/10.1155/2019/6218239 

Evgen recently confirmed in its financial results for the year ended 31 March 2019 that the read-out of its Phase IIb trial in SAH would be announced at the end of Q3 or early Q4 in the current calendar year.

Dr Stephen Franklin, CEO of Evgen, said: “This paper clearly elucidates the potential of SFX-01 in the treatment of subarachnoid haemorrhage, a condition for which there has been no material development, in terms of a new pharmacological approach, for about thirty years.  We look forward to the results of our phase II trial later this year.”